Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
For period ending 23 February 2017
 
GlaxoSmithKline plc
(Name of registrant)

 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
Yes      No x
 
 
 
 GlaxoSmithKline plc
 
(the 'Company')
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
 
Mr S Dingemans
b)
Position/status
 
Chief Financial Officer
c)
Initial notification/ amendment
 
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
 
GlaxoSmithKline plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
 
The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
£0.0000
22,448 (Deferred)
£0.0000
7,483 (Matching)
 
d)
Aggregated information
 
 
Aggregated volume
Price
29,931
£0.0000
e)
Date of the transaction
 
2017-02-22
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
 
Mr S Dingemans
b)
Position/status
 
Chief Financial Officer
c)
Initial notification/ amendment
 
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
 
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 22 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s)
and volume(s)
 
Price(s)
Volume(s)
 
£16.3850
10,763 (Deferred)
£16.4007
3,589 (Matching)
 
 
d)
Aggregated information
 
 
Aggregated volume
Price
14,352
£16.3889
e)
Date of the transaction
 
2017-02-22
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 23, 2017 
 
 
 
 
By: VICTORIA WHYTE
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc